John F Golding1, Michael A Gresty. 1. aDepartment of Psychology, University of Westminster bDivision of Brain Sciences (Neuro-Otology Unit), Imperial College London, Charing Cross Hospital, London, UK.
Abstract
PURPOSE OF REVIEW: Motion sickness remains bothersome in conventional transport and is an emerging hazard in visual information technologies. Treatment remains unsatisfactory but advances in brain imaging, neurophysiology, and neuropharmacology may provide insights into more effective drug and behavioural management. We review these major developments. RECENT FINDINGS: Recent progress has been in identifying brain mechanisms and loci associated with motion sickness and nausea per se. The techniques have included conventional neurophysiology, pathway mapping, and functional MRI, implicating multiple brain regions including cortex, brainstem, and cerebellum. Understanding of the environmental and behavioural conditions provocative of and protective against motion sickness and how vestibular disease may sensitize to motion sickness has increased. The problem of nauseogenic information technology has emerged as a target for research, motivated by its ubiquitous applications. Increased understanding of the neurophysiology and brain regions associated with motion sickness may provide for more effective medication in the future. However, the polysymptomatic nature of motion sickness, high interindividual variability, and the extensive brain regions involved may preclude a single, decisive treatment. SUMMARY: Motion sickness is an emerging hazard in information technologies. Adaptation remains the most effective countermeasure together with established medications, notably scopolamine and antihistamines. Neuropharmacological investigations may provide more effective medication in the foreseeable future.
PURPOSE OF REVIEW: Motion sickness remains bothersome in conventional transport and is an emerging hazard in visual information technologies. Treatment remains unsatisfactory but advances in brain imaging, neurophysiology, and neuropharmacology may provide insights into more effective drug and behavioural management. We review these major developments. RECENT FINDINGS: Recent progress has been in identifying brain mechanisms and loci associated with motion sickness and nausea per se. The techniques have included conventional neurophysiology, pathway mapping, and functional MRI, implicating multiple brain regions including cortex, brainstem, and cerebellum. Understanding of the environmental and behavioural conditions provocative of and protective against motion sickness and how vestibular disease may sensitize to motion sickness has increased. The problem of nauseogenic information technology has emerged as a target for research, motivated by its ubiquitous applications. Increased understanding of the neurophysiology and brain regions associated with motion sickness may provide for more effective medication in the future. However, the polysymptomatic nature of motion sickness, high interindividual variability, and the extensive brain regions involved may preclude a single, decisive treatment. SUMMARY: Motion sickness is an emerging hazard in information technologies. Adaptation remains the most effective countermeasure together with established medications, notably scopolamine and antihistamines. Neuropharmacological investigations may provide more effective medication in the foreseeable future.
Authors: Andreas Koch; Ingolf Cascorbi; Martin Westhofen; Manuel Dafotakis; Sebastian Klapa; Johann Peter Kuhtz-Buschbeck Journal: Dtsch Arztebl Int Date: 2018-10-12 Impact factor: 5.594
Authors: R J Elbin; Anthony P Kontos; Alicia Sufrinko; Mallory McElroy; Katie Stephenson-Brown; Samantha Mohler; Nathan R D'Amico; Michael W Collins Journal: J Athl Train Date: 2019-08-27 Impact factor: 2.860
Authors: Longlong Tu; Zengbing Lu; Man P Ngan; Francis F Y Lam; Claudio Giuliano; Emanuela Lovati; Claudio Pietra; John A Rudd Journal: Br J Pharmacol Date: 2020-02-03 Impact factor: 8.739
Authors: Yoon-Hee Cha; John F Golding; Behrang Keshavarz; Joseph Furman; Ji-Soo Kim; Jose A Lopez-Escamez; Måns Magnusson; Bill J Yates; Ben D Lawson Journal: J Vestib Res Date: 2021 Impact factor: 2.354
Authors: Nadine Lehnen; Fabian Heuser; Murat Sağlam; Christian M Schulz; Klaus J Wagner; Masakatsu Taki; Eberhard F Kochs; Klaus Jahn; Thomas Brandt; Stefan Glasauer; Erich Schneider Journal: PLoS One Date: 2015-08-27 Impact factor: 3.240
Authors: Qadeer Arshad; Niccolo Cerchiai; Usman Goga; Yuliya Nigmatullina; R Ed Roberts; Augusto P Casani; John F Golding; Michael A Gresty; Adolfo M Bronstein Journal: Neurology Date: 2015-09-04 Impact factor: 9.910